GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » Cash Flow from Operations

Innoveren Scientific (Innoveren Scientific) Cash Flow from Operations : $-0.92 Mil (TTM As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2023, Innoveren Scientific's Net Income From Continuing Operations was $-0.50 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $0.16 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.03 Mil. And its Cash Flow from Others was $-0.02 Mil. In all, Innoveren Scientific's Cash Flow from Operations for the three months ended in Sep. 2023 was $-0.33 Mil.


Innoveren Scientific Cash Flow from Operations Historical Data

The historical data trend for Innoveren Scientific's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoveren Scientific Cash Flow from Operations Chart

Innoveren Scientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.34 -12.29 -7.26 -4.81 -1.91

Innoveren Scientific Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.09 -0.36 -0.14 -0.33

Innoveren Scientific Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Innoveren Scientific's Cash Flow from Operations for the fiscal year that ended in Dec. 2022 is calculated as:

Innoveren Scientific's Cash Flow from Operations for the quarter that ended in Sep. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innoveren Scientific  (OTCPK:IVRN) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Innoveren Scientific's net income from continuing operations for the three months ended in Sep. 2023 was $-0.50 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Innoveren Scientific's depreciation, depletion and amortization for the three months ended in Sep. 2023 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Innoveren Scientific's change in working capital for the three months ended in Sep. 2023 was $0.16 Mil. It means Innoveren Scientific's working capital increased by $0.16 Mil from Jun. 2023 to Sep. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Innoveren Scientific's cash flow from deferred tax for the three months ended in Sep. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Innoveren Scientific's cash from discontinued operating Activities for the three months ended in Sep. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Innoveren Scientific's asset impairment charge for the three months ended in Sep. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Innoveren Scientific's stock based compensation for the three months ended in Sep. 2023 was $0.03 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Innoveren Scientific's cash flow from others for the three months ended in Sep. 2023 was $-0.02 Mil.


Innoveren Scientific Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoveren Scientific (Innoveren Scientific) Business Description

Traded in Other Exchanges
N/A
Address
2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
Executives
Fwhc Holdings, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone director 201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel officer: Chief Financial Officer 201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif officer: President and C.E.O. 19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc 10 percent owner 2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch 10 percent owner C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc 10 percent owner 334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner 10 percent owner 3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky director 2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne director, officer: Chief Executive Officer 201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford director 714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615

Innoveren Scientific (Innoveren Scientific) Headlines

From GuruFocus

Medovex Corporation Announces New Board Appointments

By Marketwired Marketwired 01-15-2019

Medovex Corporation Enters into Securities Purchase Agreement

By Marketwired Marketwired 01-16-2019

Robert Greif named Chief Executive Officer of H-CYTE

By Marketwired Marketwired 09-30-2020

Robert Greif named Chief Executive Officer of H-CYTE

By GlobeNewswire GlobeNewswire 09-29-2020

H-CYTE Announces 1-for-1,000 Reverse Stock Split

By PurpleRose PurpleRose 07-14-2022